Table of Content

1. Report Introduction

2. Mucopolysaccharidosis I Market Overview at a Glance
2.1. Market Share Distribution of Mucopolysaccharidosis I in 2018
2.2. Market Share Distribution of Mucopolysaccharidosis I in 2028

3. Disease Background and Overview: Mucopolysaccharidosis I
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Mucopolysaccharidosis I in 7MM
4.3. Total Prevalent Patient Population of Mucopolysaccharidosis I in 7MM – By Countries

5. Epidemiology of Mucopolysaccharidosis I by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.1.3. Sub-Type Specific cases of the Mucopolysaccharidosis I *Indication Specific
5.1.4. Sex- Specific Cases of the Mucopolysaccharidosis I*Indication Specific
5.1.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.1.6. Treatable Cases of the Mucopolysaccharidosis I
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.4.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.4.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.4.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.4.6. Treatable Cases of the Mucopolysaccharidosis I
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.5.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.5.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.5.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.5.6. Treatable Cases of the Mucopolysaccharidosis I
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.6.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.6.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.6.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.6.6. Treatable Cases of the Mucopolysaccharidosis I
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.7.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.7.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.7.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.7.6. Treatable Cases of the Mucopolysaccharidosis I
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.8.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.8.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.8.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.8.6. Treatable Cases of the Mucopolysaccharidosis I
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Mucopolysaccharidosis I
5.9.3. Sub-Type Specific cases of the Mucopolysaccharidosis I*

5.9.4. Sex- Specific Cases of the Mucopolysaccharidosis I*

5.9.5. Diagnosed Cases of the Mucopolysaccharidosis I
5.9.6. Treatable Cases of the Mucopolysaccharidosis I

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Mucopolysaccharidosis I

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Mucopolysaccharidosis I
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Mucopolysaccharidosis I: 7MM Market Analysis
12.1. 7MM Market Size of Mucopolysaccharidosis I
12.2. 7MM Percentage Share of drugs marketed for Mucopolysaccharidosis I
12.3. 7MM Market Sales of Mucopolysaccharidosis I by Products

13. Mucopolysaccharidosis I: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Mucopolysaccharidosis I in United States
13.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in United States
13.1.3. Market Sales of Mucopolysaccharidosis I by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Mucopolysaccharidosis I in Germany
13.2.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Germany
13.2.1.3. Market Sales of Mucopolysaccharidosis I by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Mucopolysaccharidosis I in France
13.2.2.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in France
13.2.2.3. Market Sales of Mucopolysaccharidosis I by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Mucopolysaccharidosis I in Italy
13.2.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Italy
13.2.3.3. Market Sales of Mucopolysaccharidosis I by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Mucopolysaccharidosis I in Spain
13.2.4.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Spain
13.2.4.3. Market Sales of Mucopolysaccharidosis I by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Mucopolysaccharidosis I in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in United Kingdom
13.2.5.3. Market Sales of Mucopolysaccharidosis I by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Mucopolysaccharidosis I in Japan
13.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis I in Japan
13.3.3. Market Sales of Mucopolysaccharidosis I by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight



List of Figures


Figure 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM
Figure 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 6: Diagnosed Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 7: Treatable Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 12: Treatable Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 15: Sex- Specific Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 16: Diagnosed Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 17: Treatable Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 22: Treatable Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 27: Treatable Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 31: Diagnosed Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 32: Treatable Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 37: Treatable Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 42:7MM- Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 45: United States-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 48: Germany-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 51: France-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 54: Italy-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 57: Spain-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 60:UK-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 63: Japan-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)


List of Tables


Table 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM
Table 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 5: Sex- Specific Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 6: Diagnosed Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 7: Treatable Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 11: Diagnosed Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 12: Treatable Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 14: Sub-Type Specific cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 15: Sex- Specific Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 16: Diagnosed Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 17: Treatable Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 21: Diagnosed Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 22: Treatable Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 26: Diagnosed Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 27: Treatable Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 30: Sex- Specific Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 31: Diagnosed Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 32: Treatable Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 36: Diagnosed Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 37: Treatable Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 42:7MM- Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 45: United States-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 48: Germany-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 51: France-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 54: Italy-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 57: Spain-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 60:UK-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 63: Japan-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)